logo-loader
viewIntegumen

Integumen's Gerry Brandon explains new loan facility as it fast-tracks COVID-19 test platform

 

Integumen PLC's (LON:SKIN) Gerry Brandon discusses a £400,000 loan facility that's been agreed with bioplastic specialist Cellulac Limited to help cover working capital if needed.

''What we want to do is maintain the fast-track of the COVID-19 test platform so we have the real-time detection system live in the field and on the back of that we didn't want to risk slowing it down because of working capital pressures.''

Quick facts: Integumen

Price: 2.765 GBX

AIM:SKIN
Market: AIM
Market Cap: £29.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Integumen's Gerry Brandon details new £3mln facility for Labskin and...

Integumen's (LON:SKIN) Gerry Brandon speaks to Proactive London's Andrew Scott after announcing they've secured a new £3mln three-year loan facility that requires no loan repayments until next year. He says the initial drawdown of £1.5mln provides them with sufficient working capital for its...

2 weeks ago

2 min read